<DOC>
	<DOC>NCT00874770</DOC>
	<brief_summary>The purpose of this study is to identify 1 or more doses of daclatasvir, which when used in combination with pegylated interferon alpha and ribavirin, are safe and demonstrate sufficient anti-hepatitis C virus activity.</brief_summary>
	<brief_title>Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Key Patients chronically infected with hepatitis C virus (HCV) genotype 1 HCV RNA viral load of â‰¥10*5* IU/mL (100,000 IU/mL) at screening Treatment naive Key Women of childbearing potential Cirrhosis Coinfection with HIV or hepatitis B virus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Antivirals</keyword>
</DOC>